Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maribavir vs Investigator-Assigned Treatment for Refractory/Resistant CMV in Transplant Recipients
NCT02931539Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2016
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of maribavir in cytomegalovirus infection (CMV) (2 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) at Week 8. Started Dec 2016; status: completed.
02
Drugs
maribavir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02931539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931539.